Setor Amuzu

Dr. Setor Amuzu

McGill University
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
CPCecile Le Page
Cecile Le Page
Setor AmuzuSetor Amuzu
Setor Amuzu
KRKurosh Rahimi
Kurosh Rahimi
WGWalter Gotlieb
Walter Gotlieb
JRJiannis Ragoussis
Jiannis Ragoussis
PTPatricia N. Tonin
Patricia N. Tonin

20 January 2023 in Genes
Verified
Journal Article
Open access
PDF file
CFCaitlin T. Fierheller
Caitlin T. Fierheller
WAWejdan M. Alenezi
Wejdan M. Alenezi
CSCorinne Serruya Serruya
Corinne Serruya Serruya
TRTimothée Revil
Timothée Revil
Setor AmuzuSetor Amuzu
Setor Amuzu
PTPatricia N. Tonin
Patricia N. Tonin
FANCI was recently identified as a new candidate ovarian cancer (OC)-predisposing gene from the genetic analysis of carriers of FANCI c.1813C>T; p.L605F in OC families. Here, we aimed to investigate the molecular genetic characteristics of FANCI, as they have not been described in the context of cancer. We first investigated the germline genetic landscape of two sisters with OC from the discovery FANCI c.1813C>T; p.L605F family (F1528) to re-affirm the plausibility of this candidate. As we did not find other conclusive candidates, we then performed a candidate gene approach to identify other candidate variants in genes involved in the FANCI protein interactome in OC families negative for pathogenic variants in BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, and FANCI, which identified four candidate variants. We then investigated FANCI in high-grade serous ovarian carcinoma (HGSC) from FANCI c.1813C>T carriers and found evidence of loss of the wild-type allele in tumour DNA from some of these cases. The somatic genetic landscape of OC tumours from FANCI c.1813C>T carriers was investigated for mutations in selected genes, copy number alterations, and mutational signatures, which determined that the profiles of tumours from carriers were characteristic of features exhibited by HGSC cases. As other OC-predisposing genes such as BRCA1 and BRCA2 are known to increase the risk of other cancers including breast cancer, we investigated the carrier frequency of germline FANCI c.1813C>T in various cancer types and found overall more carriers among cancer cases compared to cancer-free controls (p = 0.007). In these different tumour types, we also identified a spectrum of somatic variants in FANCI that were not restricted to any specific region within the gene. Collectively, these findings expand on the characteristics described for OC cases carrying FANCI c.1813C>T; p.L605F and suggest the possible involvement of FANCI in other cancer types at the germline and/or somatic level.

15 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Setor AmuzuSetor Amuzu
Setor Amuzu
ECEuridice Carmona
Euridice Carmona
AMAnne-Marie Mes-Masson
Anne-Marie Mes-Masson
CGCelia M.T. Greenwood
Celia M.T. Greenwood
PTPatricia N. Tonin
Patricia N. Tonin
JRJiannis Ragoussis
Jiannis Ragoussis
The benefit of PARP inhibitor olaparib in relapsed and advanced high-grade serous ovarian carcinoma (HGSOC) is well established especially in BRCA1/2 mutation carriers. Identification of additional biomarkers can help expand the population of patients most likely to benefit from olaparib treatment. To identify candidate markers of olaparib response we analyzed genomic and in vitro olaparib response data from two independent groups of cancer cell lines. Using pan-cancer cell lines (n = 896) from the Genomics of Drug Sensitivity in Cancer database, we applied linear regression methods to identify statistically significant gene predictors of olaparib response based on mRNA expression. We then analyzed whole exome sequencing and mRNA gene expression data from our collection of 18 HGSOC cell lines previously classified as sensitive, intermediate, or resistant based on in vitro olaparib response for mutations, copy number variation and differential expression of candidate olaparib response genes. We identify genes previously associated with olaparib response (SLFN11, ABCB1), and discover novel candidate olaparib sensitivity genes with known functions including interaction with PARP1 (PUM3, EEF1A1) and involvement in homologous recombination DNA repair (ELP4). Further investigations at experimental and clinical levels are required to validate novel candidates, and ultimately determine their efficacy as potential biomarkers of olaparib sensitivity.

16 October 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
Setor AmuzuSetor Amuzu
Setor Amuzu
AXAmy X. Xie
Amy X. Xie
XBXuechun Bai
Xuechun Bai
KPKelly R. Pekala
Kelly R. Pekala
NPNicholas A. Pickersgill
Nicholas A. Pickersgill
JCJian Carrot-Zhang
Jian Carrot-Zhang
Genetic similarity of populations (or genetic ancestry) is associated with differences in somatic alterations in cancers. We meta-analyze two targeted panel sequencing cohorts with 275,605 samples from 14 cancer types. Here we find a recurrent depletion of TERT promoter mutations in patients of African and East Asian ancestry across multiple cancers. Several clinically actionable alterations, such as ERBB2 mutations in lung adenocarcinoma and MET mutations in papillary renal cell carcinoma, occur at a higher frequency in patients of non-European ancestry. Furthermore, in both cohorts, we show depletions in total driver alterations in non-European ancestries in multiple cancer types, potentially reflecting biases in current panel-based testing that prioritize established targets derived from predominantly patients of European ancestry. Our study highlights a need to increase population diversity in genomic studies to find new drivers and enhance precision oncology interventions for all populations.

17 January 2022 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
Setor AmuzuSetor Amuzu
Setor Amuzu
LFLili Fu
Lili Fu
NDNadine Demko
Nadine Demko
BRBarbara Rivera
Barbara Rivera
CDCeline Domecq
Celine Domecq
WFWilliam Foulkes
William Foulkes

15 May 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
Setor AmuzuSetor Amuzu
Setor Amuzu
TRTimothée Revil
Timothée Revil
WFWilliam D. Foulkes
William D. Foulkes
JRJiannis Ragoussis
Jiannis Ragoussis
Background: Target enrichment coupled with next generation sequencing provide high-throughput approaches for screening several genes of interest. These approaches facilitate screening a panel of genes for mutations associated with inherited breast cancer for research, diagnostic, and genetic counseling applications. Objective: To evaluate the performance of our custom 13 gene breast cancer panel, based on singleplex PCR, developed by WaferGen BioSystems. The panel was evaluated using patient-derived DNA samples, in terms of target enrichment efficiency, off-target enrichment, uniformity of target capture, effect of GC content of target regions on coverage depth, and concordance with validated variant calls. Results: At least 90% of target sequence for each gene was captured at 30x or greater. We evaluated uniformity of target capture across samples by calculating the percentage of samples with at least 90% of total target captured at 100x or greater and found 92% (33/36 samples) uniformity for our panel. Off-target enrichment ranges between 7.2% and 22.3%. We found perfect concordance between our custom panel and the Qiagen human breast cancer panel for functionally annotated variant calls in high read depth shared target regions. Altogether, there was agreement between the panels for 779 variants at 41 loci. We also confirmed 10 pathogenic mutations, initially discovered by Sanger sequencing, in the appropriate samples following target enrichment using our custom WaferGen panel. Conclusion: Our custom hereditary breast cancer panel is sensitive to the desired target genes and facilitates deep sequencing for reliable variant calling.